Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes and chronic kidney disease in primary and secondary cardiovascular prevention groups: Results from the randomized CREDENCE trial

Circulation Jul 18, 2019

Mahaffey KW, et al. - Given that canagliflozin attenuates renal failure risk in patients with type 2 diabetes and chronic kidney disease, researchers explored its impacts on specific cardiovascular outcomes as well as in those without prior cardiovascular disease (primary prevention). Participants (n=4,401) were patients with type 2 diabetes and chronic kidney disease. In a random manner, these patients received canagliflozin or placebo with optimized standard of care. Relative to secondary prevention participants (N=2,220; 50.4%), the primary prevention participants (N=2181; 49.6%) had younger age, shorter diabetes duration, and were more often female. In patients with type 2 diabetes and chronic kidney disease, including those without prior cardiovascular disease, a significant reduction in major cardiovascular events and kidney failure was evident in relation to treatment with canagliflozin.

Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen